Comparison of the efficacy of regorafenib generics and original drugs

Regorafenib is an oral, small molecule, multi-target tyrosine kinase inhibitor that is widely used in the treatment of advanced metastatic colorectal cancer, gastrointestinal stromal tumors, hepatocellular carcinoma and other solid tumors. In actual clinical practice, with the widespread use of regorafenib, the comparison between original drugs and generic drugs has become one of the focuses of concern for patients. The original drug was developed by Bayer (Bayer) with the trade name Stivarga. It has accumulated a large amount of clinical data and safety evidence since its global launch. Generic drugs mainly come from pharmaceutical companies in India, Bangladesh, Laos and other countries. Most of these versions are produced in accordance with international generic drug standards. The active ingredients, dosage, and specifications of the drugs are consistent with the original drugs.

From the perspective of efficacy, there is no significant difference in the chemical composition of generic drugs and original drugs, and they meet the equivalence standard, that is, the effective blood drug concentration, onset time and metabolism in the body are basically the same. Many third-party tests and clinical experiences have shown that the performance of the generic version in controlling disease conditions and delaying tumor progression is basically the same as that of the original drug. It provides patients with a more cost-effective choice, especially when resources are limited or medical insurance coverage is insufficient. Take India's Natco, Laos' Lucius and other pharmaceutical companies as examples. Their generic versions of regorafenib have been actually used by many patients and are widely exported to Asian and Middle Eastern countries.

However, the core challenge of generic drugs is not the difference in efficacy, but their production quality control and drug stability. Some low-quality generic drugs may have impurity issues or inconsistent bioavailability. Therefore, when choosing generic drugs, patients should give priority to reputable international pharmaceutical manufacturers to ensure that the sources of drugs are regular. In mainland China, because some generic drugs have not yet received registration approval from the State Food and Drug Administration and can only be obtained through overseas medical channels, it is recommended to evaluate individual suitability under the guidance of a doctor before use.

Reference materials:https://www.stivarga-us.com/